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Abstract

Schizophrenia is complex to treat, as individuals with the disorder have high
hospital readmission rates due to medication noncompliance. According to the American
Psychiatric Association (2017), mental health disparities negatively influence access to
care and health outcomes in minority and vulnerable populations including people with
schizophrenia. Research indicates that long-acting injectable (LAI) antipsychotic
medication could increase treatment adherence and reduce hospital readmission rates in
individuals with schizophrenia. The purpose of this quality improvement project was to
investigate mental health disparities among individuals with schizophrenia at a large
hospital in Miami, Florida from June 2020 to December 2020. A quantitative research
approach was used with a descriptive, retrospective, cross-sectional design to conduct
this project. Data such as gender, age, and LAI antipsychotic medication was collected
and examined from a sample of 120 individuals with schizophrenia. Results revealed that
males and younger adults, aged 49 years and under, were more frequently prescribed LAI
antipsychotic medication than females and older adults at a large hospital in Miami,
Florida from June 2020 to December 2020. While Haldol Decanoate and Invega Sustenna
were most prescribed to individuals with schizophrenia, Abilify Aristada and
Fluphenazine Decanoate were the least prescribed. Nurses and health care providers are
called to eliminate health disparities among individuals with schozophrenia globally and
nationally.
Keywords: schizophrenia, long-acting injectable antipsychotic medication, mental
health disparity, advanced practice nursing
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DNP PROJECT REPORT
INTRODUCTION
Schizophrenia is a serious mental illness that affects individuals across the
lifespan and throughout the lifetime (Targum et al., 2016). Schizophrenia affects an
individual’s perception, thought process, emotion, and behavior. Individuals with
schizophrenia experience alterations in sensations or perceptions, significantly impacting
their biological, psychological, and social domains (American Psychiatric Association
[APA], 2020). The hallmarks of schizophrenia include positive symptoms such as
hallucinations, delusions, paranoia, and disorganized thoughts or speech, as well as
negative symptoms such as social isolation, depression, anhedonia, or flat affect (APA,
2020). Psychotic symptoms of schizophrenia are present for 6 months or greater in
individuals with the condition (APA, 2020). The disease also affects an individual’s
cognitive function that includes gradual decreases in attention, concentration, and
memory (APA, 2020). Symptoms of schizophrenia usually appear in late adolescents or
young adults in males and 20- to 30-year-old females (Hafner, 2019).
The prevalence of individuals with schizophrenia is 1% worldwide (Magliocco et
al., 2020). A cross-sectional study reported that individuals with schizophrenia are three
times at higher risk for mortality than those without the condition (Gatov et al., 2017).
Suicide and accidental deaths are also high among individuals with schizophrenia
(Lomholt et al., 2019). Other causes of death include cancer, cardiovascular disease,
somatic symptom, and related disorders (Lomholt et al., 2019). The causes of increased
rates of somatic diseases among individuals with schizophrenia include poor lifestyle
choices, unhealthy diet, lack of exercise, smoking, and obesity (Lomholt et al., 2019).
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Mental illnesses are complex and difficult to treat, especially populations with
schizophrenia, as they have high hospital readmission rates due to medication
noncompliance (Shameer et al., 2018). Over half of individuals with schizophrenia are
not compliant with treatment (Lu et al., 2020; Magliocco et al., 2020). According to the
American Psychiatric Association (2017), mental health disparity plays a role in
accessibility of care, treatment, and healthcare outcomes. Psychosocial factors related to
mental health disparities among racial and ethnic minority populations are often
unaddressed in clinical practice (American Psychiatric Association, 2017). Psychiatric
providers will continue to face challenges in the care of individuals with schizophrenia
without addressing mental health disparities. Stigma related to mental illness could also
contribute to medication noncompliance among populations with schizophrenia
(Haftman, 2017). In addition, clinical and knowledge gaps among healthcare providers
regarding mental illness especially in schizophrenia are countless (Haftman, 2017).
Hospitals in the United States (U.S.) have attempted to reduce readmission rates
in this population (Shameer et al., 2018). Unfortunately, individuals with schizophrenia
have higher hospital readmission rates compared to individuals without the condition
(Shameer et al., 2018). Medication noncompliance among individuals with schizophrenia
contributes to high hospital readmission rates in this population. Reducing hospital
readmission rates and related health disparities in this population could decrease
healthcare costs in the U.S. (Shameer, et al., 2018).
According to the Centers for Disease Control and Prevention (2015), over
300,000 visits to the emergency department (ED) are attributed to this population
annually. About 33% of these ED visits required acute care, with 17% being transferred

DISPARITIES IN SCHIZOPHRENIA

9

to a psychiatric hospital from 2009 to 2011 (CDC, 2015). A cross-sectional study
indicated that 21% of individuals with schizophrenia had an unplanned hospital
readmission in 2018 (Health Services Advisory Group, 2019). Schizophrenia is also an
economic burden to individuals, families, communities, and the U.S. healthcare system
(Shah et al., 2018). Without addressing hospital readmission rates and related issues in
this area, the U.S. economy will continue to be negatively affected. According to Cloutier
et al. (2016), costs related to schizophrenia amounted to $174.3 billion in 2013. The
major economic cost of schizophrenia is unemployment, and the major economic impact
is the direct and indirect healthcare costs of schizophrenia, which was $37.7 billion in
2013 (Cloutier et al., 2016).
Several treatment options are available for individuals with schizophrenia. Both
oral antipsychotic medications and long-acting injectable antipsychotic medications
(LAIs) are available for individuals with schizophrenia to help decrease positive and
negative symptoms. Reasons for medication noncompliance with oral antipsychotic
medication in this population include poor insight of medications, side effects of
medications, complex medication regimen, and lack of medication effectiveness (Lu et
al., 2020; Shah et al., 2018). However, LAIs for individuals with schizophrenia help to
increase medication compliance and decrease hospital readmissions by eliminating the
need for daily dosing (Lin et al., 2020). Long-acting injectable antipsychotic medications
prevent decompensation of the disease (Magliocco et al., 2020; Olagunju et al., 2019).
Knowing the benefits of LAIs would help clinicians understand if LAIs should be the
standard treatment for populations with schizophrenia. New treatment options for this
population could increase mental health outcomes; however, if clinicians do not address
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health disparities, then individuals, families, and communities affected with
schizophrenia will be at a disadvantage (American Psychiatric Association, 2017). The
purpose of this quality improvement project was to investigate mental health disparities
among individuals with schizophrenia at a large hospital in Miami, Florida from June
2020 to December 2020.
Problem Statement
Reducing hospital readmissions could decrease healthcare costs in the United
States (U.S.). However, individuals with schizophrenia have increased hospital
readmission rates (Cook et al., 2020; Magliocco et al., 2020; Shameer et al.,
2018). Research suggests that medication noncompliance and mental health disparities
could negatively contribute to the clinical problem among this population (Das-Munshi et
al., 2018; Munday et al., 2019; Lin et al., 2020; Magliocco et al., 2020). If a quality
improvement project is not conducted in this area, then individuals with schizophrenia
may continue to have high hospital readmission rates, negatively affecting the U.S.
healthcare economy.
Advanced Literature Review
The purpose of this quality improvement project was to investigate mental health
disparities among individuals with schizophrenia at a large hospital in Miami, Florida
from June 2020 to December 2020. Researchers conducted an advanced literature review
to identify gaps in the literature related to phenomena of interest. A literature review was
conducted by this researcher using the Cumulative Index of Nursing and Allied Health
Literature (CIHNAL), Medical Literature Analysis and Retrieval System Online
(MEDLINE), Psychology Info (PsycINFO), and key terms long-acting injectable
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antipsychotic medication and schizophrenia and hospital readmission. Search limitations
included articles within 5 years (2015 to 2020) and full-text research peer-reviewed
articles written in English. Articles with relevant concepts such as schizophrenia,
psychotic disorders, long-acting antipsychotic medications, and health disparities were
selected. A total number of 12 articles were selected and examined by this researcher.
Gaps in the literature and three content areas were identified: (a) Long-acting injectable
antipsychotic medication use among individuals with schizophrenia; (b) Long-acting
injectable antipsychotic medication use among diverse populations with schizophrenia;
and (c) Long-acting injectable antipsychotic medication use and hospital readmission.
The three content areas will be explored in the subsequent paragraphs.
Long-Acting Injectable Antipsychotic Medication Use Among Individuals with
Schizophrenia
This content area analyzes long-acting injectable antipsychotic medications
(LAIs) use among individuals with schizophrenia worldwide including in the U.S.
Researchers examined compliance rates, recovery degrees, preferences, and cognitive
improvements between oral antipsychotic and LAIs. Four studies were identified under
this content area. The studies were placed in chronological order by year.
Shah et al. (2018) analyzed differences in treatment patterns, healthcare
utilization, and costs among individuals in the United States who were recently diagnosed
with schizophrenia and received oral antipsychotics or LAIs. The researchers used a
retrospective design and convenience sampling method to conduct the study.
Investigators collected data from 2,302 subjects who were over 18 years old. Researchers
reported that individuals with LAI were more likely to remain on medication regimens
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compared to individuals with oral antipsychotics. Although there are reductions in
inpatient treatment costs, LAI medications are expensive, resulting in similar total
healthcare costs for individuals on LAIs versus those treated with oral antipsychotics.
Future studies should assess antipsychotic medication compliance and demographic
variables.
Olagunju et al. (2019) analyzed the effects of LAIs on psychosocial function in
individuals with schizophrenia in Australia. The researchers conducted a systematic
review and meta-analyses of the literature using PRISMA. Investigators collected data
from 45 studies and 8,616 subjects over the age of 18 years. Researchers reported
individuals with LAIs showed higher recovery of psychosocial function compared to
placebo. There was no difference between the type of LAI prescribed and the degree of
psychosocial function. Future researchers should analyze predictors of long-term
psychosocial function among individuals using LAIs.
Blackwood et al. (2020) analyzed factors that determined individual preferences
for LAI or oral antipsychotic medication to better understand patient expectations and
reduce barriers to LAI use in schizophrenia in multiple countries including the United
States. The researchers used patient-reported questionnaires from a double-blind
randomized controlled study. Researchers collected data from 1,402 subjects.
Researchers reported that patient empowerment and quality-of-life-related goals were
important for individuals who preferred LAI antipsychotics over oral antipsychotics.
Individuals also chose less-frequent, quarterly LAI over monthly ones and daily oral
medications when given options. Future studies should examine patient populations that
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closely represent patients in clinical practice and real clinical practice and real-world
settings.
Magliocco et al. (2020) analyzed possible modifications of cognitive performance
among individuals who were diagnosed with schizophrenia and treated with secondgeneration LAIs in Italy. The researchers used an observational, non-randomized study
design. Investigators collected data from 32 subjects. Researchers reported individuals
with second-generation LAIs showed improvement in neurocognitive function after 1
year of treatment. There were not many differences between the type of LAI prescribed
and cognitive performance. However, there were social and cognitive improvements in
individuals who switched to second-generation LAIs from oral antipsychotic treatment.
Long-Acting Injectable Antipsychotic Medication Use among Diverse Populations
with Schizophrenia
This content area explores LAI use among diverse populations with schizophrenia
globally and in the U.S. Researchers examined potential moderating factors including
age, gender, ethnicity, and LAIs on treatment outcomes for individuals receiving LAIs.
Four studies were identified under this content area. The studies were placed in
chronological order by year.
Targum et al. (2016) analyzed whether age or gender were potential moderating
factors on treatment outcomes for individuals receiving LAIs or placebo in seven
countries located in North America, Europe, and Asia. The researchers used a doubleblind placebo-controlled study. Researchers collected data from 596 subjects who were
aged 18 to 70 years old. Researchers reported that age and gender were not moderating
factors on the treatment response. LAI, specifically aripiprazole lauroxil (Aristada),
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regardless of the dosages, showed favorable outcomes. Individuals of all age and gender
groups with LAIs showed shorter hospitalization and a significant improvement
compared to those with placebo. The authors recommended future studies to assess
potential moderating factors.
Das-Munshi et al. (2018) analyzed whether there were differences in evidencebased treatments among ethnic minority groups in the United Kingdom. The researchers
used a representative cross-sectional study. Investigators collected data from 10,512
individuals diagnosed with schizophrenia or schizoaffective disorder. Researchers
reported non-Hispanic Blacks were more likely to be prescribed LAIs and less likely to
be offered Clozaril treatment for treatment-resistant psychosis compared to non-Hispanic
Whites. All other ethnic minority groups were less likely to be offered cognitive
behavioral therapy. Non-Hispanic Blacks were also less likely to be offered family
therapy and Asians were less likely to receive copies of care plans. There were ethnic
minority disparities in psychotropic medication use and access to psychological
treatments and care plans. Future research should assess differences in prescribing
Clozaril by ethnicity for those with treatment-resistant psychosis.
Patel et al. (2018) analyzed the effectiveness of paliperidone compared to other
LAIs in the United Kingdom. The researchers used a retrospective study and collected
data from 1,281 individuals who were aged between 16 and 65 years. Researchers
reported Paliperidone palmitate was the most prescribed LAI for individuals who had
more frequent and longer hospital admissions before LAI treatment. There were no
differences in the effectiveness between Paliperidone palmitate and other LAIs.
Therefore, individuals can be treated with any LAIs depending on symptoms and
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financial status, since Paliperidone palmitate is the most expensive LAI. The authors
suggested future studies to assess the effectiveness of paliperidone compared to other
LAIs when given to individuals with severe schizophrenia.
Lin et al. (2020) analyzed the effect of LAIs and oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly individuals with schizophrenia in
Taiwan. The researchers used a cohort retrospective, observational design, as well as
convenience sampling method to conduct the study. Investigators collected data from
1,272 subjects who were at least 60 years old and diagnosed with schizophrenia or
schizoaffective disorders. Researchers reported elderly individuals with LAIs showed
significantly lower re-hospitalization rates and a longer time to re-hospitalization within 1
year of discharge. The shorter hospitalizations were associated with individuals with
LAIs. The authors recommended future studies to assess the effectiveness of LAIs in
elderly individuals with schizophrenia.
Long-Acting Injectable Antipsychotic Medication Use and Hospital Readmission
This content area explores LAI medication use and hospital readmission globally
and in the U.S. Researchers examined potential moderating factors including LAIs or oral
antipsychotic medication on treatment outcomes for individuals with schizophrenia and
hospital readmission. Four studies were identified under this content area. The studies
were placed in chronological order by year.
MacEwan et al. (2016) analyzed hospital readmission rates of individuals who
were treated with LAIs or oral antipsychotics for schizophrenia treatment upon hospital
discharges. The researchers used a retrospective cohort study and convenience sampling
technique. The researchers collected data from 1,450 subjects who were age 18 to 64
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years and were hospitalized for schizophrenia symptoms. Researchers reported that
individuals with LAIs showed a significantly lower probability of hospital readmissions
compared to individuals with oral antipsychotics. The authors recommended future
studies to evaluate differences based on the frequency of past hospitalization.
Tiihonen et al. (2017) analyzed the effectiveness of LAIs and oral antipsychotic
treatments for the prevention of hospital readmission in Sweden. The researchers used a
prospective population-based cohort study. Investigators collected data from 29,823
subjects aged 16 to 64 years old. Researchers reported that individuals with clozapine and
LAIs had the lowest rate of relapse in schizophrenia which prevents hospital
readmissions as well. The researchers showed approximately 20% to 30% lower risk of
re-hospitalization while getting LAIs compared to getting oral antipsychotics.
Munday et al. (2019) analyzed early initiation of long-acting injectable
antipsychotic treatment hospitalization rates in the U.S. The researchers used a
retrospective cohort. Investigators collected data from 2,366 subjects aged 18 years old
and over. Researchers reported that individuals with LAI initiation within 1 year of a
diagnosis of schizophrenia episode showed lower hospitalization rates and healthcare
costs. On the other hand, the individuals with LAI initiation more than 1 year after a new
episode of schizophrenia showed higher hospitalization rates and healthcare costs.
Therefore, early use of LAI may benefit and affect better treatment management,
adherence, relapse rates, and other outcomes. The authors recommended future studies to
evaluate outcomes associated with differential treatment in first-episode schizophrenia
versus new episodes that occur farther in life.
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Lu et al. (2020), analyzed long-acting injectable antipsychotic treatments
regarding the quality of care and outcomes of individuals with schizophrenia in a
community-based outpatient clinic in the United States. The researchers used an
observational retrospective design to conduct the study. Investigators collected data from
23 subjects aged over 18 years and who have received LAIs for schizophrenia or
schizoaffective disorder. Researchers reported the individuals with LAIs exhibit
favorable knowledge about LAIs, a positive attitude toward medications, and satisfaction
with care. The individuals with LAIs also showed a decrease in hospitalizations/
emergency room visits after receiving LAIs. The authors recommended for future studies
to evaluate the effects of LAIs compared with oral psychotics.
A synthesis of the literature related to these content areas suggests that individuals
on LAIs exhibit favorable outcomes, higher satisfaction rates, and increased medication
compliance rates (Blackwood et al., 2020; Lu et al., 2020; Shah et al., 2018). Individuals
with schizophrenia who were placed on LAIs show significantly lower hospital
readmissions and a shorter hospital stay positively impacting healthcare costs (Lu et al.,
2020; MacEwan et al., 2016; Munday et al., 2019; Tiihonen et al., 2017). Also, treatment
with LAIs showed preferable improvement in patient status (Magliocco et al., 2020;
Olagunju et al., 2019). The treatments with LAIs, especially the second-generation
antipsychotics, showed increased patient outcomes. However, the only negative aspect of
using LAIs is the cost of the medication, which may negatively impact patient
compliance (Shah et al., 2018). Furthermore, although researchers have explored the
positive effects of LAI medication use, they neglected to analyze mental health
disparities among individuals with schizophrenia in the U.S. Decreasing health disparities
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is imperative in the healthcare system. The purpose of this quality improvement project is
to investigate mental health disparities among individuals with schizophrenia using longacting antipsychotic medication at a large hospital in Miami, Florida from June 2020 to
December 2020.
Significance
This project was significant in the discipline of nursing. It had implications for
nursing practice, research, and health policy.
Significance to Nursing Practice
This quality improvement project could increase awareness regarding mental
health disparity among individuals with schizophrenia in Miami, Florida. The findings of
this project could help nurses develop interventions for individuals with schizophrenia.
Nurses in practice could use the results of the study to improve healthcare outcomes in
this population. It also allowed nurses and clinicians to gain new knowledge to improve
the efficacy of patient care. Nurses could decrease health disparities in this population by
understanding the significance of the project.
Significance to Nursing Research
This quality improvement project could encourage nurse researchers to further
investigate and address mental health disparity among individuals with schizophrenia
using long-acting antipsychotic medication (LAIs). It could increase research in mental
health and bridge knowledge gaps in nursing practice. This quality improvement project
could also unveil new knowledge and improve psychiatric nursing care as well as
healthcare outcomes in individuals with schizophrenia. Results of this project could
reduce mental health disparities and improve patient outcomes. Findings of this project
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could also be used to support and advance nursing practice in the care of individuals with
schizophrenia using long-acting antipsychotic medication.
Significance of Health Policy
This quality improvement project could bridge knowledge gaps by helping nurses
develop policies that improve mental health outcomes among individuals with
schizophrenia. This quality improvement project may also provide significant data to
nurses and healthcare providers and improve healthcare policies at a large hospital in
Miami, Florida. Results of this project could improve policies related to psychiatric care
for individuals with schizophrenia at a large hospital in Miami, Florida. Changes in
healthcare policies are needed to reduce health disparities in this population (American
Psychiatric Association, 2017).
Purpose
The purpose of this quality improvement project was to investigate mental health
disparities among individuals with schizophrenia at a large hospital in Miami, Florida
from June 2020 to December 2020.
PICO Clinical Questions
1. Were males with schizophrenia more frequently prescribed long-acting injectable
antipsychotic medication than females at a large hospital in Miami, Florida from June
2020 to December 2020?
2. Were younger individuals with schizophrenia, ages 49 years and below, more frequently
prescribed long-acting injectable antipsychotic medication than older individuals, ages 50
years and over, at a large hospital in Miami, Florida from June 2020 to December 2020?
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3. Which long-acting injectable antipsychotic medication (Haldol Decanoate; Abilify
Maintena; Invega Sustenna, Abilify Aristada, Risperdal Consta, or Fluphenazine
Decanoate) was most prescribed at a large hospital in Miami, Florida from June 2020 to
December 2020?
4. Which long-acting injectable antipsychotic medication (Haldol Decanoate; Abilify
Maintena; Invega Sustenna, Abilify Aristada, Risperdal Consta, or Fluphenazine
Decanoate) was least prescribed at a large hospital in Miami, Florida from June 2020 to
December 2020?
Definition of Terms
The variables of this study were gender, age, and long-acting injectable
antipsychotic medication. These variables were discussed in the subsequent sections.
Gender
Gender referred to the sex of the individual with schizophrenia using long-acting
injectable antipsychotic medication at a large hospital in Miami, Florida from June 2020
to December 2020. Gender also represented demographic data. Gender was categorized
for this study as follows: (a) male or (b) female.
Age
Age referred to the years of the individual with schizophrenia using long-acting
injectable antipsychotic medication at a large hospital in Miami, Florida from June 2020
to December 2020. Age was also demographic data. Age was grouped as follows: (a) 18
to 49 years or (b) 50 years and over.
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Long-Acting Injectable Antipsychotic Medication
This variable referred to the LAI that the individual with schizophrenia was
prescribed at a large hospital in Miami, Florida from June 2020 to December 2020. This
variable was also demographic data. The variable was categorized as follows: (a) Haldol
Decanoate; (b) Abilify Maintena; (c) Invega Sustenna; (d) Abilify Aristada; (e) Risperdal
Consta; (f) Fluphenazine Decanoate.
Conceptual Underpinning of the Project
Quantitative research was conducted under the positivist paradigm. This quality
improvement project was conducted under the worldview of positivism. Positivism was
developed in the 1830s by Auguste Comte (1798 to 1857) who held the philosophical and
political movement (Pawlikowski et al., 2018). There were four constructs of:
determinism, empiricism, parsimony, and generality. First, determinism was the idea that
all events are determined by previously existing causes (Williams, 2020). Secondly,
empiricism was the idea that all knowledge comes from experiences (Williams, 2020).
Third, parsimony was the idea that a theory should be explained in the simplest possible
form (Williams, 2020). Lastly, generality was the idea that the abstract and the particular
have relationship (Williams, 2020).
The concept of positivism allowed advanced practice nurses to gain an
understanding of quantitative research and helped them to apply quantitative concepts to
patient care. This research used the paradigm of positivism to conduct this quality
improvement project. A descriptive, retrospective, cross-sectional design was used to
conduct this study. This researcher assessed mental health disparity among individuals
with schizophrenia at a large hospital in Miami, Florida from June 2020 to December
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2020. Differences between gender, age, and LAI antipsychotic medication were assessed
among individuals with schizophrenia at a large hospital in Miami, Florida from June
2020 to December 2020.
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DNP PROJECT REPORT
METHODOLOGY
The purpose of this quality improvement project was to investigate mental health
disparities among individuals with schizophrenia at a large hospital in Miami, Florida
from June 2020 to December 2020. Reducing mental health disparities is critical to
increase health outcomes for populations with schizophrenia and improve psychiatric
care in the U.S. The researcher explored the study design, setting, sample, inclusion
criteria, exclusion criteria, measures and instruments, data collection procedures, data
analysis, and protection of human subjects in the subsequent paragraphs.
Study Design
A quantitative research approach was used to conduct this quality improvement
project. In particular, a descriptive, retrospective, cross-sectional design was used to
conduct this quality improvement project. These study designs were described in the
proceeding sections.
Descriptive Design
Descriptive design was used by quantitative researchers to gain more information
about a phenomenon of interest (Grove et al., 2015). The purpose of this design was to
accurately and systematically describe characteristics of a situation, population, or
phenomenon (Grove et al., 2015). It was also used for examining variables, developing
conceptual or operational definitions of variables, or describing phenomena (Grove et al.,
2015). This researcher used the descriptive design to describe mental health disparities
among individual with schizophrenia using long-acting injectable antipsychotic
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medication at a large hospital in Miami, Florida from June 2020 to December 2020. The
variables to be explored were gender, age, and LAI type.
Retrospective Design
The retrospective design required the collection of existing data from the
electronic medical record or other recorded information to investigate a phenomenon of
interest (von Lucadou et al., 2019). The outcomes of the topic of interest have already
occurred, and researchers collect data from the records (Ranganathan & Aggarwal, 2018).
Chart review was a method of this design (Ranganathan & Aggarwal, 2018). Researchers
collected existing data to compare and analyze variables. This researcher used a
retrospective design to collect de-identified existing data from individuals with
schizophrenia using LAI antipsychotic medication at a large hospital in Miami, Florida
from June 2020 to December 2020.
Cross-Sectional Design
A cross-sectional design was a type of observational study. Researchers used this
design to examine outcomes and exposures in a group of subjects simultaneously (Setia,
2016). This design was widely used to investigate the prevalence of diseases or for
population-based surveys. The cross-sectional design was cost effective compared to
other quantitative study designs.
PICO Clinical Questions
1. Were males with schizophrenia more frequently prescribed long-acting injectable
antipsychotic medication than females at a large hospital in Miami, Florida from June
2020 to December 2020?
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2. Were younger individuals with schizophrenia, ages 49 years and below, more frequently
prescribed long-acting injectable antipsychotic medication than older individuals, ages 50
years and over, at a large hospital in Miami, Florida from June 2020 to December 2020?
3. Which long-acting injectable antipsychotic medication (Haldol Decanoate; Abilify
Maintena; Invega Sustenna, Abilify Aristada, Risperdal Consta, or Fluphenazine
Decanoate) was most prescribed at a large hospital in Miami, Florida from June 2020 to
December 2020?
4. Which long-acting injectable antipsychotic medication (Haldol Decanoate; Abilify
Maintena; Invega Sustenna, Abilify Aristada, Risperdal Consta, or Fluphenazine
Decanoate) was least prescribed at a large hospital in Miami, Florida from June 2020 to
December 2020?
Setting
This quality improvement project was conducted in Miami, Florida. The
researcher collected de-identified data of individuals with schizophrenia using longacting injectable antipsychotic medication at a large hospital in Miami, Florida from June
2020 to December 2020.
Sample
The estimated sample size for this study was N = 175 subjects. The researcher
reached this sample size based on experience working as a psychiatric nurse at a large
hospital in Miami, Florida for the past 7 years. About 20 to 25 individuals with
schizophrenia on LAI were screened and evaluated per month at a large hospital in
Miami, Florida inpatient units.
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Inclusion Criteria
Individuals who suffer from schizophrenia and were treated at a large hospital in
Miami, Florida from June 2020 to December 2020 were included in this project. Also,
individuals with schizophrenia who were placed on LAIs were considered for this
project.
Exclusion Criteria
Individuals who suffer from other conditions other than schizophrenia were
excluded from this project. Individuals who were not treated with LAI antipsychotic
medication at a large hospital in Miami, Florida from June 2020 to December 2020 were
excluded from this project. Individuals outside of the time frame (June 2020 to December
2020) were not included in this project.
Measures and Instruments
De-identified data of individuals with schizophrenia using LAIs at a large hospital
in Miami, Florida from June 2020 to December 2020 were collected in counts. This
researcher collected de-identified data using a researcher-developed demographic
instrument. Demographic variables were collected in counts per month from June 2020 to
December 2020. The investigator collected the following demographic variables using a
researcher-developed instrument: (a) gender (a. male or b. female); (b) age (a. 18 to 49
years or b. 50 years and older); and (c) LAI antipsychotic medication (a. Haldol
Decanoate, b. Abilify Maintena, c. Invega Sustenna, d. Abilify Aristada, e. Risperdal
Consta, or f. Fluphenazine Decanoate).

DISPARITIES IN SCHIZOPHRENIA

27

Data Collection Procedures
First, this researcher obtained Institutional Review Board (IRB) approval from
Florida International University (FIU) and then the hospital before collecting data. The
researcher also obtained a support letter from the unit director at the hospital to collect
de-identified data of individuals with schizophrenia using long-acting injectable
antipsychotic medications from June 2020 to December 2020. Upon permission from the
unit director, the researcher collected de-identified data in counts using a researcherdeveloped demographic instrument. The researcher started collecting data from June
2020 to December 2020. Then the researcher repeated the process and collected data in
counts by gender (a. male or b. female); age (a. 18 to 49 years and b. 50 years and over);
and LAI antipsychotic medication (a. Haldol Decanoate; b. Abilify Maintena; c. Invega
Sustenna; d. Abilify Aristada; e. Risperdal Consta; or f. Fluphenazine Decanoate).
Data Analysis
The data was generated from deidentified data and analyzed by the researcher
using Microsoft Excel. Data were examined using descriptive analysis. Descriptive
analysis allowed the researcher to organize data and provided an idea of the distribution
of data (Grove et al., 2015). This statistical method also provided meaning to data (Grove
et al., 2015). Means (M), median (Mdn), and standard deviation (SD) were part of
descriptive analysis and this researcher conducted these calculations for the variables of
this project. Most variables for this study were nominal (gender, LAI type). However,
age was a ratio variable.
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Protection of Human Subjects
Institutional Review Board (IRB) approvals from FIU and the hospital were
obtained before the researcher conducted the project to ensure research ethics and
protection of human subjects. The investigator also completed the Collaborative
Institutional Training Initiative (CITI) ethics certification for the protection of human
subjects in social and behavioral research. De-identified data was collected in counts;
therefore, data collection was anonymous. A letter of support was also obtained from a
unit director. Only the investigator had access to the data. There were no hard copies of
the data. De-identified demographic data of subjects was stored in a password-protected
USB drive. The USB drive was stored and protected in the home-office of researcher in a
locked file cabinet where the researcher was the only person who had access to the data.
No known risks or benefits were associated with this study; however, the study assessed
mental health disparities among individuals with schizophrenia using LAIs to potentially
decrease mental health disparities.
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DNP PROJECT REPORT
RESULTS
The purpose of this quality improvement project was to investigate mental health
disparities among individuals with schizophrenia at a large hospital in Miami, Florida
from June 2020 to December 2020. Reducing mental health disparities is critical to
increase health outcomes for individuals with schizophrenia and improve psychiatric care
in the U.S. Data were collected and analyzed by the researcher to answer each PICO
clinical question.
A total of 120 individuals with schizophrenia were treated with long-acting
injectable antipsychotic medication at a large hospital in Miami, Florida from June 2020
to December 2020 (see Table 1). Psychiatric providers prescribed the most LAI
antipsychotic medication in November 2020 and the least in September 2020 (M = 17;
Mdn = 16; SD = 3.87). During these 2 months, men were proscribed LAI antipsychotic
medication at higher ratios than women.
Table 1
Number of LAI Antipsychotic Medication Prescribed by Gender From June 2020 to
December 2020 at a Large Hospital in Miami, Florida (N = 120)

Female
Male
Other
Total

June

July

August

8
13
0
21

6
9
0
15

5
15
0
20

September October November December
2
10
0
12

7
9
0
16

8
14
1
23

4
9
0
13

Total
40
79
1
120

DISPARITIES IN SCHIZOPHRENIA

30

Restatement of PICO Clinical Questions
PICO Clinical Question One
PICO clinical question one was: Were males with schizophrenia more frequently
prescribed long-acting injectable antipsychotic medication than females at a large
hospital in Miami, Florida from June 2020 to December 2020? Results revealed that
males with schizophrenia were more frequently prescribed long-acting injectable
antipsychotic medication than females at a large hospital in Miami, Florida from June
2020 to December 2020 (see Figure 1). Nearly 80 males were prescribed long-acting
injectable antipsychotic medication, while 40 females received LAI antipsychotic
medication at a large hospital in Miami, Florida from June 2020 to December 2020. One
individual with an unknown gender received a LAI antipsychotic medication during this
time period. However, that person was registered as an adult. The number of males who
received LAI antipsychotic medication were almost double than that of females during
the same time period.
Figure 1
Gender Distribution Among Individuals With Schizophrenia Prescribed LAI Between
June 2020 and December 2020 at a Large Hospital in Miami, Florida (N = 120)

Gender Distribution
Male

Female
1%

33%
66%

Other
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PICO Clinical Question Two
PICO clinical question two was: Were younger individuals with schizophrenia,
ages 49 years and below, more frequently prescribed long-acting injectable antipsychotic
medication than older individuals, ages 50 years and over, at a large hospital in Miami,
Florida from June 2020 to December 2020? Results revealed that younger individuals
with schizophrenia, ages 18 to 49 years, were more frequently prescribed long-acting
injectable antipsychotic medication than older individuals, ages 50 years and over, at a
large hospital in Miami, Florida from June 2020 to December 2020 (see Figure 2). More
than 80 individuals with schizophrenia, ages 49 years and below, received LAI
antipsychotic medication while less than 40 individuals with schizophrenia, ages 50 years
and older, received LAI antipsychotic medication during this time period. The number of
younger individuals who were prescribed LAI antipsychotic medications were more than
twice that of older individuals.
Furthermore, people in their 30s were most prescribed LAI antipsychotic
medication at a large hospital in Miami Florida from June 2020 to December 2020, (see
Table 2). Approximately 1 of 4 individuals prescribed a LAI antipsychotic medication
was in their 30s. The second age group that was prescribed LAI antipsychotic medication
the most were individuals in their 20s (n = 27). No individuals between the ages of 70
and 79 years received LAI antipsychotic medication. Individuals with schizophrenia in
their 50s and 60s were prescribed LAI antipsychotic medication at approximately similar
frequencies.
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Figure 2
Age Group Differences in Individuals With Schizophrenia Using LAI Between June 2020
and December 2020 at a Large Hospital in Miami, Florida (N = 120).

Age Distribution
100
80
60
84

40
20

36

0
18 - 49 years old

50 years old or above

Table 2
Age Distribution Among Individuals With Schizophrenia Prescribed LAI Antipsychotic
Medication From June 2020 to December 2020 at a Large Hospital in Miami, Florida
(N=120)

Haldol
Decanoate
Abilify
Maintena
Invega
Sustenna
Abilify
Aristada
Risperdal
Consta
Fluphenazine
Decanoate
Total

10s

20s

30s

40s

50s

60s

70s

80s

Total

0

3

7

10

6

7

0

0

33

0

5

6

2

2

3

0

0

18

2

11

10

3

5

2

0

0

33

0

4

5

3

1

1

0

0

14

0

4

6

3

3

5

0

0

21

0

0

0

0

0

0

0

1

1

2

27

34

21

18

17

0

1

120
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PICO Clinical Question Three
PICO clinical question three was: Which long-acting injectable antipsychotic
medication (Haldol Decanoate; Abilify Maintena; Invega Sustenna, Abilify Aristada,
Risperdal Consta, or Fluphenazine Decanoate) was most prescribed at a large hospital in
Miami, Florida from June 2020 to December 2020? Haldol Decanoate and Invega
Sustenna were the most prescribed long-acting injectable antipsychotic medications at a
large hospital in Miami, Florida from June 2020 to December 2020 (see Figure 3). Each
of these LAI antipsychotic medications was prescribed to over 30 individuals (27%).
Risperdal Consta was the next most prescribed medication, and nearly 20% of individuals
with schizophrenia received this medication. However, both Abilify Maintena and
Aristada were prescribed to less than 20 individuals (15%) with schizophrenia.
Furthermore, Abilify Maintena and Invega Sustenna were the most prescribed LAI
antipsychotic medications for females and Haldol Decanoate for males at a large hospital
in Miami, Florida from June 2020 to December 2020 (see Table 3). Haldol Decanoate
was three times more prescribed to males than females.
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Figure 3
LAI Antipsychotic Medication Distribution Among Individuals With Schizophrenia at a
Large Hospital in Miami, Florida From Jene 2020 To December 2020 (N = 120)

LAI Antipsychotic Medication Distribution
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Table 3
Distribution of LAI Antipsychotic Medication Prescribed by Gender at a Large Hospital
in Miami, Florida from June 2020 to December 2020 (N=120)
Haldol
Abilify
Invega
Abilify Risperdal Fluphenazine Total
Decanoate Maintena Sustenna Aristada Consta
Decanoate
Female
7
10
10
7
6
0
40
Male
26
8
22
7
15
1
79
Other
0
0
1
0
0
0
1
Total
33
18
33
14
21
1
120
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PICO Clinical Question Four
The PICO clinical question four was: Which long-acting injectable antipsychotic
medication (Haldol Decanoate; Abilify Maintena; Invega Sustenna, Abilify Aristada,
Risperdal Consta, or Fluphenazine Decanoate) was least prescribed at a large hospital in
Miami, Florida from June 2020 to December 2020? Abilify Aristada and Fluphenazine
Decanoate were least prescribed at 11.7% and 1%, respectively, at a large hospital in
Miami, Florida from June 2020 to December 2020. In particular, fewer than 15
individuals with schizophrenia were prescribed Abilify Aristada, which was less than half
of all individuals who received Haldol Decanoate or Invega Sustenna during this time
frame. However, the second least prescribed LAI antipsychotic medication by gender was
Risperdal Consta for females, and Abilify Aristada for males (see Table 3).
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DNP PROJECT REPORT
SUMMARY AND DISCUSSION
The purpose of this quality improvement project was to investigate mental health
disparities among individuals with schizophrenia at a large hospital in Miami, Florida
from June 2020 to December 2020. Data was collected and analyzed among individuals
with schizophrenia prescribed long-acting injectable antipsychotic medication at a large
hospital in Miami, Florida from June 2020 to December 2020. A descriptive,
retrospective, cross-sectional design was used to conduct this research. A researcherdeveloped demographic instrument was employed to collect data. Convenience sampling
technique was used for collecting data and recruiting subjects. Microsoft Excel was used
for data analysis.
Results revealed that a total of N = 120 subjects were prescribed LAI
antipsychotic medication at a large hospital in Miami, Florida from June 2020 to
December 2020. Males and younger adults, ages 49 years and below, were more
frequently prescribed LAI antipsychotic medication than females and older adults.
Furthermore, Haldol Decanoate and Invega Sustenna were the most prescribed LAI
antipsychotic medication. However, Abilify Aristada and Fluphenazine Decanoate were
the least prescribed. The researcher will compare and contrast the findings of the project
with current literature. This section will additionally discuss implications for advanced
practice nursing, limitations of the project, recommendations, and conclusions.
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Summary of the Results and Discussion
This research was conducted in Miami, Florida. Currently, the largest ethnic
group in Miami, Florida are Hispanics at 69.4% (U.S. Census Bureau, 2021). NonHispanic Blacks currently represent 17.7% of the population in Miami, Florida, followed
by non-Hispanic Whites (12.9%), and Asian make up 1.6% of the population in the
region (U.S. Census Bureau, 2021). More than 50% of the population in Miami were
born in foreign country (U.S. Census Bureau, 2021). Nearly 20% of the population in
Miami, Florida lack healthcare insurance and live in poverty (U.S. Census Bureau, 2021).
Median household income in Miami, Florida was $51,347 (U.S. Census Bureau, 2021),
although national median household income in 2019 was $68,703 (Semega et al., 2020).
These factors contribute to mental health disparities in Miami, Florida.
Results of this project indicated that more males (n = 79) were treated for
schizophrenia with long-acting injectable antipsychotic medication than females (n = 40)
at a large hospital in Miami, Florida from June 2020 to December 2020. However, a
cross-sectional study by the Substance Abuse and Mental Health Services Administration
(SAMHSA, 2020) consisting of N = 40,154 Americans found that females (n = 26,726)
were more likely to access mental health treatment than males (n = 13,428) in
2019. Results of this project were likely affected by the COVID-19 pandemic, a period of
uncertainty that forced medical offices to close or change care delivery methods, as well
as people to quarantine due to the coronavirus disease (Zhang, 2021). Other factors that
influence access to care include ethnicity among gender groups. Caplan (2019) conducted
a cross-sectional study (N = 64) with the purpose of investigating beliefs and attitudes
toward mental illness in Hispanic faith-based communities and reported that Hispanics (n
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= 17 males; n = 47 females) are less frequently treated for mental health
conditions compared to non-Hispanic Whites because of denial and stigma of mental
illness.
Another cross-sectional study by Henry et al. (2020) assessed attitude toward
mental health treatment in the U.S. and reported that non-Hispanic Blacks (n = 5160
males; n = 7475 females) had higher negative attitudes than non-Hispanic Whites (n =
12223 males; n = 13513 females). Henry et al. (2020) also found that non-Hispanic
Blacks (5%) were less likely to be treated for mental health disorders than non-Hispanic
Whites (9.9%). Furthermore, although Asians consist of a small population in MiamiDate County, Florida, Wu et al. (2018) conducted a cross-sectional study (N = 361,488)
with the purpose of investigating mental health diagnosis and treatment among Asian
Americans (N = 16,418; n = 6,457 males; n = 9,961 females) and non-Hispanic Whites
(N = 345,070; n = 146,992 males; n = 198,078 females) and revealed that Asian
Americans (8.5%) were diagnosed and treated at significantly lower frequencies than that
of non-Hispanic Whites (15%).
Furthermore, results of this project revealed that younger adults (n = 84), aged 18
to 49 years, were more likely to receive LAI antipsychotic medication than older adults
(n = 36), aged 49 years and older at a large hospital in Miami, Florida from June 2020 to
December 2020. Similarly, a SAMHSA (2020) study of Americans with psychiatric
disorders showed that younger adults (18 to 49 years old, n = 23,688) received more
treatment than older adults (50 years or older, n = 16,466). Blumberg et al. (2015)
conducted a cross-sectional study (N = 21,058) and examined differences between access
to mental health care, ethnicity and age groups. The researchers reported that non-
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Hispanic Black and Hispanic young adults (aged 18 to 44 years, 26.4%) were less likely
to seek treatment than non-Hispanic White young adults (45.4%) (Blumberg et al., 2015).
However, older non-Hispanic Blacks and Hispanics, ages 45 years and over, were more
likely to access mental health treatment than non-Hispanic Whites of the same age group
(Blumberg et al., 2015). Lipson et al. (2018) also conducted a survey (N = 43,375) with
the purpose of investigating disparities among college students in the U.S. and found that
non-Hispanic White young adults (45.5%) accessed mental health treatment at higher
ratios compared to non-Hispanic Black (25.5%) and Hispanic young adults (33%).
Furthermore, Wu et al. (2018) reported that non-Hispanic Whites were more likely to
access to mental treatment than Asian Americans across the lifespan.
Results of this projects showed that Invega Sustenna (n = 33) and Haldol
Decanoate (n = 33) were the most prescribed long-acting injectable antipsychotic
medications at a large hospital in Miami, Florida from June 2020 to December 2020.
Haldol is a first-generation antipsychotic medication, known to have increased side
effects; however, Haldol is commonly used in clinical practice because it is effective and
affordable (McEvoy et al., 2014). McEvoy et al. (2014) conducted a multisite, doubleblind, randomized clinical trial (N = 311) with the purpose of comparing the effectiveness
of Paliperidone Palmitate (Invega Sustenna) and Haloperidol (Haldol) Decanoate and
found that Haloperidol Decanoate was associated with more serious side effects than
Paliperidone Palmitate (Invega Sustenna). However, Rosenheck et al. (2016) reported
that Haldol Decanoate was more cost-effective and showed slightly less benefits than
Paliperidone Palmitate (Invega Sustenna). Therefore, Haldol Decanoate may benefit
people who lack healthcare insurance or face financial issues.
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Furthermore, some LAI antipsychotic medications require supplementation with
oral antipsychotic medication for few weeks after initiating LAI treatment. However, a
randomized controlled trial by Emsley and Kilian (2018) investigated the advantages of
Invega Sustenna and showed that the LAI antipsychotic medication is safe, effective, and
has a fast onset of action that does not require overlap with oral antipsychotic
supplementation. Also, Invega Sustenna is the only LAI antipsychotic medication
approved by the Food and Drug Administration for schizoaffective disorder and proved
to reduce mood symptoms (Mayo Clinic, 2019). Overall, Invega Sustenna has favorable
outcomes and less adverse reactions compared to Haldol Decanoate although it requires
two loading doses initially and the price of the medication may not be affordable for
people without healthcare insurance or financial issues.
Lastly, the results of this project indicated that Abilify Aristada (n = 14) and
Fluphenazine Decanoate (n = 1) were the least prescribed LAI at a large hospital in
Miami, Florida from June 2020 to December 2020. Fluphenazine is a typical
antipsychotic medication that is associated with increased adverse effects but affordable
compared to other atypical antipsychotic medications. Olfson et al. (2007) conducted a
study consisting of N = 461 subjects to compare administrative data for 3 LAI
antipsychotic medications (Haldol, Fluphenazine, and Risperdal) before, during, and after
consumption and found that older non-Hispanic Whites are more likely to be prescribed
this LAI antipsychotic medication than other ethnic or age groups. Furthermore, Abilify
Aristada is an expensive LAI antipsychotic medication; therefore, psychiatric
professionals may be reluctant to prescribe this medication for populations that face
financial issues (Karas et al., 2019). Prescribers may also lean toward other LAI
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antipsychotic medications since Abilify Aristada requires two doses initially and is
known for increased risks of akathisia (Raedler, 2016). Also, prescribers may think
Abilify Aristada is not useful since there is no available dosage equivalent to maximum
oral dosage of 30mg.
Implications for Advanced Practice Nursing
Advanced practice nurses (APNs) should reduce health disparities in
schizophrenia by focusing on minority populations and individualizing antipsychotic
medication regimen based on sociodemographic characteristics and affordability for
continuous care. It is imperative for APNs to increase awareness regarding mental health
disparities in this population in the U.S. Such awareness and education could improve
health outcomes in individuals with schizophrenia. Furthermore, APNs could use the
results of this project to develop strategies for minority populations with schizophrenia.
Nurse leaders and administrators could advocate for policies that improve healthcare
delivery and ultimately health outcomes in this population. Moreover, APNs should
collaborate with politicians to eliminate health disparities in individuals with
schizophrenia by supporting social movements and political parties that advocate for the
needs of this population and address social determinants of health in the U.S.
Limitations of the Project
Projects have limitations; therefore, limitations of this project were:
1. Convenience sampling method was utilized to access data and recruit subjects; however,
convenience sampling does not involve randomization.
2. A descriptive, retrospective, cross-sectional study design cannot be used to describe
causality between the variables.
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3. The researcher was limited with variables; therefore, future researchers should collect
essential data such as race or ethnicity of subjects and hospital readmission rates among
individuals with schizophrenia to comprehensively explore health disparities in this
group.
Recommendations
Future researchers should employ longitudinal study designs to discover causation
between the variables such as types of LAI antipsychotic medications, ethnicity and
hospital readmission rates. Researchers should also use qualitative designs to access indepth subjective data among individuals with schizophrenia prescribed LAI antipsychotic
medication. Researchers should explore other locations in the U.S. with large ethnic
minority populations such as Asians and Native Americans with schizophrenia to reduce
health disparities nationally. In addition, researchers should assess healthcare providers’
knowledge awareness of health disparities among minority populations with
schizophrenia.
Conclusions
Results of this quality improvement project revealed that males were more
frequently prescribed LAI antipsychotic medication than females at a large hospital in
Miami, Florida from June 2020 to December 2020. Younger adults, ages 49 years and
under, were more frequently prescribed LAI antipsychotic medication than older adults,
ages 50 years and above, at a large hospital in Miami, Florida during the same time
frame. Furthermore, Haldol Decanoate and Invega Sustenna were the most prescribed
LAI antipsychotic medication, while Abilify Aristada and Fluphenazine Decanoate were
the least prescribed at a large hospital in Miami, Florida from June 2020 to December
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2020. Nurses and healthcare providers are called to assess and eliminate health disparities
among individuals with schizophrenia globally and nationally.
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APPENDIX E: DEMOGRAPHIC INSTRUMENT
RESEARCHER-DEVELOPED DEMOGRAPHIC INSTRUMENT
De-identified data will be collected and received in counts from a large hospital in
Miami, Florida. It will consist of demographics from subjects who were treated at M a
large hospital in Miami, Florida from June 2020 to December 2020.
1. Age: Age refers to the years of the individual with schizophrenia using long-acting
injectable antipsychotic medication at a large hospital in Miami, Florida from June 2020
to December 2020. Age is also demographic data. Age will be grouped as follows: 1) 18
to 49 years; 2) 50 years and over.
o 18 to 49 years: ___
o 50 years or older: ___
2. Gender: Gender refers to the sex of the individual with schizophrenia using long-acting
injectable antipsychotic medication at a large hospital in Miami, Florida from June 2020
to December 2020. Gender is also demographic data. Gender will be categorized for this
study as follows: a) male; or b) female.
o Male: ___
o Female: ___
o Other: ____
3. Type of Long-Acting Injectable antipsychotic medication: This variable refers to the LAI
that the individual with schizophrenia was prescribed at a large hospital in Miami, Florida
from June 2020 to December 2020. This variable is also demographic data. The variable
will be categorized as follows: a) Haldol Decanoate; b) Abilify Maintena; and c) Invega
Sustenna; d) Abilify Aristada; e) Risperdal Consta; or f) Fluphenazine Decanoate
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o Haldol Decanoate: ___
o Abilify Maintena: ___
o Invega Sustenna: ___
o Abilify Aristada: ___
o Risperdal Consta: ___
o Fluphenazine Decanoate: ___
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